GamaMabs Pharma
Develops innovative monoclonal antibodies against cancer
GamaMabs Pharma has raised €18M across 2 funding rounds from 4 investors, most recently a Series B round in Dec 2015. Based in Toulouse, France; founded 2013; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€18M
€18,100,000
Funding rounds
2
Investors
4
distinct backers
Active since
2013-09
latest 2015-12
Funding by year
EUR raised per yearGamaMabs Pharma — funding by year — interactive chart.
Data table
| GamaMabs Pharma — funding by year | |
|---|---|
| 2013 | €3.1M |
| 2015 | €15M |
Signals
High confidenceRaise-next likelihood10
base rate 48% for Series B
- ▼ Dormant (no round in 3+ cohort gaps)
- ▲ Up-round momentum
- ▼ Low backer re-investment
Exit likelihood8
base rate 11% (2+ rounds)
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2015-12-01 | Series B | €15M | Alto Invest,Edmond de Rothschild Venture Capital,iXO Private Equity | View deal → |
| 2013-09-01 | Series A | €3.1M | Bpifrance | View deal → |
Similar companies
same sector or country- Mistral AI€6.5BFrance · AI
- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData